From discovery to the clinic: The novel DNA methylation biomarker mSEPT9 for the detection of colorectal cancer in blood

Epigenomics

Volumn 2, Issue 4, 2010, Pages 575-585

  Payne, Shannon R ^a  

^a EPIGENOMICS AG   (Germany)

Author keywords

biomarker; blood; colorectal cancer; DNA methylation; early detection; in vitro diagnostic; SEPT9

Indexed keywords

TUMOR MARKER;

CANCER DIAGNOSIS; CANCER SCREENING; COLON MUCOSA; COLONOSCOPY; COLORECTAL CANCER; CPG ISLAND; DNA METHYLATION; EARLY DIAGNOSIS; GENE; HUMAN; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SEPTIN 9 GENE;

COLORECTAL NEOPLASMS; DNA METHYLATION; DNA RESTRICTION ENZYMES; EARLY DETECTION OF CANCER; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; SEPTINS; TUMOR MARKERS, BIOLOGICAL; VALIDATION STUDIES AS TOPIC;

EID: 77955442473     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.10.35     Document Type: Review

References (46)

1. Laird PW, Jaenisch R: The role of DNA methylation in cancer genetic and epigenetics. Annu. Rev. Genet. 30, 441-464 (1996).
2. Wolffe AP, Matzke MA: Epigenetics: regulation through repression. Science 286(5439), 481-486 (1999).
3. Issa JP: The epigenetics of colorectal cancer. Ann. NY Acad. Sci. 910, 140-153; discussion 153-1145 (2000).
4. Markowitz SD, Bertagnolli MM: Molecular origins of cancer: molecular basis of colorectal cancer. N. Engl. J. Med. 361(25), 2449-2460 (2009).
5. Kramer BS, Croswell JM: Cancer screening: the clash of science and intuition. Annu. Rev. Med. 60, 125-137 (2009).
6. Mandel JS, Bond JH, Church TR et al.: Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota colon cancer control study. N. Engl. J. Med. 328(19), 1365-1371 (1993).
7. Winawer SJ, Zauber AG, Ho MN et al.: Prevention of colorectal cancer by colonoscopic polypectomy. The national polyp study workgroup. N. Engl. J. Med. 329(27), 1977-1981 (1993).
8. Baxter NN, Goldwasser MA, Paszat LF, Saskin R, Urbach DR, Rabeneck L: Association of colonoscopy and death from colorectal cancer. Ann. Intern. Med. 150(1), 1-8 (2009).
9. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J. Clin. 59(4), 225-249 (2009).
10. Hofstetter W, Swisher SG, Correa AM et al.: Treatment outcomes of resected esophageal cancer. Ann. Surg. 236(3), 376-384; discussion 384-1375 (2002).
11. Internullo E, Moons J, Nafteux P et al.: Outcome after esophagectomy for cancer of the esophagus and GEJ in patients aged over 75 years. Eur. J. Cardiothorac. Surg. 33(6), 1096-1104 (2008).
12. Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD: The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J. Urol. 150(2 Pt 1), 379-385 (1993).
13. Warren JL, Klabunde CN, Mariotto AB et al. : Adverse events after outpatient colonoscopy in the medicare population. Ann. Intern. Med. 150(12), 849-857, W152 (2009).
14. Allen JD, Barlow WE, Duncan RP et al.: NIH state-of-the-science conference draft statement: enhancing use and quality of colorectal screening. NIH Consens. State Sci. Statements 27(1), 1-21 (2010).
15. Mandel JS, Church TR, Bond JH et al.: The effect of fecal occult-blood screening on the incidence of colorectal cancer. N. Engl. J. Med. 343(22), 1603-1607 (2000).
16. Shapiro JA, Seeff LC, Thompson TD, Nadel MR, Klabunde CN, Vernon SW: Colorect a l ca ncer test use from the 20 05 national health interview survey. Cancer Epidemiol. Biomarkers Prev. 17(7), 1623-1630 (2008).
17. Mandel P, Metais P: Les acides nucleiques du plasma sanguin chez l'homme. C. R. Seances Soc. Biol. Fil. 142(3-4), 241-243 (1948).
18. O'Mullan P, Craft D, Yi J, Gelfand CA: Thrombin induces broad spectrum proteolysis in human serum samples. Clin. Chem. Lab. Med. 47(6), 685-693 (2009).
19. Laird PW: Principles and challenges of genome-wide DNA methylation analysis. Nat. Rev. Genet. 11(3), 191-203
20. Lofton-Day C, Lesche R: DNA methylation markers in patients with gastrointestinal cancers. Current understanding, potential applications for disease management and development of diagnostic tools. Dig. Dis. 21(4), 299-308 (2003).
21. Gonzalgo ML, Liang G, Spruck CH 3rd, Zingg JM, Rideout WM 3rd, Jones PA: Identification and characterization of differentially methylated regions of genomic DNA by methylation-sensitive arbitrarily primed PCR. Cancer Res. 57(4), 594-599 (1997).
22. Toyota M, Ho C, Ahuja N et al.: Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res. 59(10), 2307-2312 (1999).
23. Shi H, Yan PS, Chen CM et al.: Expressed CpG island sequence tag microarray for dual screening of DNA hypermethylation and gene silencing in cancer cells. Cancer Res. 62(11), 3214-3220 (2002).
24. Fassbender A, Lewin J, Konig T et al.: Quantitative DNA methylation profiling on a high-density oligonucleotide microarray. Methods Mol. Biol. 576, 155-170 (2010).
25. Model F, Osborn N, Ahlquist D et al.: Identification and validation of colorectal neoplasia-specific methylation markers for accurate classification of disease. Mol. Cancer Res. 5(2), 153-163 (2007).
26. Sozzi G, Conte D, Leon M et al.: Quantification of free circulating DNA as a diagnostic marker in lung cancer. J. Clin. Oncol. 21(21), 3902-3908 (2003).
27. Papadopoulou E, Davilas E, Sotiriou V et al.: Cell-free DNA and RNA in plasma as a new molecular marker for prostate and breast cancer. Ann. NY Acad. Sci. 1075, 235-243 (2006).
28. Weiss G, Rosch T: Potential of a new blood test for colorectal cancer screening - the septin 9 gene biomarker. European Oncology 6(1), 1-4 (2010).
29. Lofton-Day C, Model F, Devos T et al.: DN A met hylation bioma rkers for blood- based colorectal cancer screening. Clin. Chem. 54(2), 414-423 (2008).
30. Hartwell LH, Culotti J, Reid B: Genetic control of the cell-division cycle in yeast. I. Detection of mutants. Proc. Natl Acad. Sci. USA 66(2), 352-359 (1970).
31. Hall PA, Russell SE: The pathobiology of the septin gene family. J. Pathol. 204(4), 489-505 (2004).
32. Russell SE, Mcilhatton MA, Burrows JF et al. : Isolation and mapping of a human septin gene to a region on chromosome 17q, commonly deleted in sporadic epithelial ovarian tumors. Cancer Res. 60(17), 4729-4734 (2000).
33. Strehl S, Konig M, Meyer C et al.: Molecular dissection of t(11; 17) in acute myeloid leukemia reveals a variety of gene fusions with heterogeneous fusion transcripts and multiple splice variants. Genes Chromosomes Cancer 45(11), 1041-1049 (2006).
34. Kreuziger LM, Porcher JC, Ketterling RP, Steensma DP: A mixed-lineage leukemia- SEPT9 fusion and t(11;17)(q23;q25) associated with de novo myelodysplastic syndrome. Leuk. Res. 31(8), 1145-1148 (2007).
35. McDade SS, Hall PA, Russell SE: Translational control of SEPT9 isoforms is perturbed in disease. Hum. Mol. Genet. 16(7), 742-752 (2007).
36. Pepe MS, Etzioni R, Feng Z et al.: Phases of biomarker development for early detection of cancer. J. Natl Cancer Inst. 93(14), 1054-1061 (2001).
37. Bossuyt PM, Reitsma JB, Bruns DE et al.: Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for reporting of diagnostic accuracy. Clin. Chem. 49(1), 1-6 (2003).
38. Devos T, Tetzner R, Model F et al.: Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin. Chem. 55(7), 1337-1346 (2009).
39. Hall HI, Van Den Eeden SK, Tolsma DD et al.: Testing for prostate and colorectal cancer: comparison of self-report and medical record audit. Prev. Med. 39(1), 27-35 (2004).
40. Brenner H, Hoffmeister M, Stegmaier C, Brenner G, Altenhofen L, Haug U: Risk of progression of advanced adenomas to colorectal cancer by age and sex: estimates based on 840,149 screening colonoscopies. Gut 56(11), 1585-1589 (2007).
41. Ross JS: Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome. Adv. Anat. Pathol. 16(4), 204-215 (2009).
42. Gibbs J: Regulatory pathways for molecular dx: detailing the various options available and what each requires. Genetic Engineering & Biotechnology News 28(14), 1 (2008).
43. Slodkwoska EA, Ross JS: Mammaprint 70-gene signature: another milestone in personalized medical care for breast cancer patients. Expert Rev. Mol. Diagn 9(5), 417-422 (2009).
44. Identifier NCT00855348 www.clinicaltrials.gov
45. US FDA: Guidance for Industry and FDA Staff: In Vitro Diagnostic Studies; Frequently Asked Questions; Availability (2007) www.regulations.gov/search/ Regs/home.html #documentDetail?R=0900006480b0a038
46. US FDA: Guidance for Industry, Clinical Laboratories, and FDA Staff on In Vitro Diagnostic Multivariate Index Assays (2007) www.regulations.gov/search/ Regs/home . html#docketDetail?R=FDA-2006-D-0233